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Abstract
Background. Cystatin C, a marker of renal function,
has been shown to be an independent predictor of
cardiovascular disease (CVD) in older adults, but few
data are available in middle-aged adults. Moreover,
no study has compared cystatin C and microalbumi-
nuria as risk factors for CVD outcomes in middle-aged
adults, and it is not known whether cystatin C is
related to an early stage of atherosclerosis.
Methods. We evaluated the relationships between
serum creatinine, estimated glomerular filtration rate
(GFR), serum cystatin C (all divided into tertiles),
microalbuminuria and carotid atherosclerosis in a
population-based random sample of 523 adults aged
35–64 years from the Seychelles (Indian Ocean). GFR
was estimated using the modification of diet in renal
disease (MDRD) equation. Intima-media thickness
(IMT) was assessed by B-mode ultrasound.
Results. The mean age of the study sample was 52
years, and 55% were women. Carotid IMT was higher
in participants with microalbuminuria (802 vs 732 mm,
P< 0.001) and was inversely associated with GFR
tertiles (from 728 to 809 mm, P for trend¼ 0.002). IMT
was not associated with cystatin C or creatinine (P for
trend¼ 0.10 and 0.16, respectively). In multivariate
analyses adjusted for cardiovascular risk factors,
the association between microalbuminuria and IMT
remained (P¼ 0.047), while the association between
GFR and IMT disappeared (P for trend¼ 0.33).
Conclusions. Microalbuminuria, but not cystatin C,
is associated with carotid atherosclerosis beyond
traditional cardiovascular risk factors among
middle-aged adults. Cystatin C does not have a
stronger relationship with carotid atherosclerosis in
middle-aged adults than creatinine.
Keywords: Africa; albuminuria; atherosclerosis;
cystatin; Seychelles
Introduction
Cardiovascular diseases (CVD) are the leading causes
of mortality and morbidity in western and developing
countries [1,2]. Screening and treatment is one strategy
for the primary prevention of CVD, but the highest-
risk patients should be identified to maximize the
benefit/cost ratio of treatments [3]. In recent years,
several tests, ranging from serum to urinary markers,
have been proposed as new cardiovascular risk factors
or markers that may improve risk prediction and help
to identify the highest-risk patients [4,5]. Among
markers of renal function that have been associated
with increased cardiovascular risk, cystatin C has
recently been shown to be an independent predictor
of cardiovascular events in a prospective cohort of
adults aged 65 years [6]. Microalbuminuria has also
been suggested as an independent predictor of cardio-
vascular events, including in subjects without diabetes
[7]. The presence of chronic kidney disease, either
manifested by albuminuria or reduced estimated
glomerular filtration rate (GFR), appears to be an
independent risk factor for CVD in prospective studies,
particularly in high-risk populations [7].
It remains to be determined whether a mild decrease
in GFR or other early markers of renal dysfunction
are associated with increased cardiovascular risk in
low-risk populations [7]. The association of micro-
albuminuria with cardiovascular events has, indeed,
been less consistent in low-risk populations [7,8].
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The association between cystatin C and CVD has been
mainly studied in prospective cohorts of older adults
who have a higher prevalence of renal dysfunction
[6,9]. These two markers have also not been compared
in a same population, and it is not known whether
cystatin C is related to an early stage of atherosclerosis.
To that end, we compared the associations of serum
cystatin C and microalbuminuria with the risk of
carotid atherosclerosis in a population-based sample of
middle-aged adults in the Seychelles Islands.
Subjects and methods
Subjects and design
Description of the population. The Republic of Seychelles
is a group of islands in the Indian Ocean 1800 km east of
Kenya, and is part of the African region. A large majority of
the population is of African descent. Health care, including
medications, is available at no direct cost at the point of
delivery to all residents through a national health system
while a few private doctors also provide services on a fee for
service basis. All deaths are registered in Seychelles, and vital
statistics indicate a life expectancy of 69 years in men and
76 years in women. AIDS and CVD account for, respec-
tively, 1 and 38% of total mortality [10].
A population-based survey of cardiovascular risk factors
was conducted in 2004 under the auspices of the Ministry of
Health of the Republic of Seychelles (Seychelles Heart Study
III), as previously described [11]. In summary, the sampling
frame consisted of a sex- and age-stratified random sample of
the entire population aged 25–64 years. The survey was
approved by theMinistry of Health after technical and ethical
reviews. Participants were free to participate, and gave written
informed consent. The participation rate was 80.2%.
Study sample. Among the 1255 participants, ultrasonogra-
phy was performed in all participants above 45 years seen
during a 17-week period (n¼ 496), as well as in a randomly
selected sample (18%, n¼ 58) of the participants aged 35–44
years. We restricted the investigation to these age classes
because they were more likely to have atherosclerosis.
Among these 554 participants, we excluded those with
unreliable values of microalbuminuria because of menstrua-
tion or gynaecological and/or urinary tract infection (n¼ 2),
similar to previous studies [12]. We also excluded those with
missing data for microalbuminuria, serum cystatin or serum
creatinine (n¼ 19). Participants with proteinuria (albumin/
creatinine >300mg/g) were also excluded, because of the
small number (n¼ 10) and similar to previous studies using
semi-quantitative measurement of microalbuminuria [13,14].
The final sample of the analyses consisted of 523
participants.
Measurements
Renal function assays. Fasting serum samples were
obtained in all participants and were stored at 708C.
Serum cystatin C was measured by means of a particle-
enhanced immunonephelometric assay with a nephelometer
(BNII, Dade Behring) [6]. The range of detection of the assay
is 0.195–7.330mg/l, with the reference range for young,
healthy persons reported as 0.53–0.95mg/l. A previous study
has shown that the assay remained stable, even after freezing
[6]. Microalbuminuriawas measured on a spot of second
morning urine after an overnight fast using the Bayer
Clinitek Status analyser that has been shown to be a reliable
screening procedure for microalbuminuria [15]. It provides
semi-quantitative estimation of urinary albumin excretion
adjusted to creatininuria, and determines participants with
microalbuminuria (30–300mg albumin/g creatinine) and
those with normal albuminuria (<30mg/g) [16,17]. Serum
creatinine was measured by means of a kinetic Jaffe method
(Hitachi 917, Japan; reagents from Roche Diagnostics). We
estimated GFR using the abbreviated modification of diet in
renal disease (MDRD) equation [18].
Carotid ultrasound. B-mode ultrasound imaging of the
carotid wall is a well-established surrogate marker for
atherosclerotic disease that is increasingly used in observa-
tional and interventional studies [19]. All the scans and image
analyses were carried out by the same investigator (P.Y.) who
was blinded to the risk factor status of the participants. High
resolution B-mode ultrasonography was conducted with
an ultrasound system (General Electric LOGIQ Book)
connected with a 6–10MHz linear array transducer and
equipped with a software for arterial wall analysis (M’ATH,
ICN-metric, Paris, France) to perform semi-automatic
measures of intima-media thickness (IMT) on frame [20].
The IMT was measured on the far wall of both common
carotid arteries over a length of 1 cm on a reference site
located 2 cm below the bifurcation, and the average of the left
and the right maximum common carotid IMT was computed
[21,22]. The far wall was used because of higher reproduci-
bility and possible overestimation of the IMT of the near wall
[22]. The recorded IMT was the mean thickness measured
along the whole segment.
To examine the reproducibility, 20 randomly selected
ultrasound measurements were performed twice by the same
sonographer. For carotid IMT, intra-observer variability
showed a coefficient of variation of 4.8% between first and
second readings, similar to previous studies [23].
Covariates. Smoking was defined as current smoking of
1 cigarette/day. Blood pressure was defined as the average
of the last two of three measurements with a mercury
sphygmomanometer taken at intervals 2min after the
participants had been seated for 30 min. Hypertension
was defined as use of anti-hypertensive medications or
measured systolic blood pressure 140 and/or diastolic
90mmHg. To calculate body mass index (BMI), weight
was measured with electronic medical scales and height with
fixed stadiometers (Seca, Germany). Blood lipids and plasma
glucose were measured after fasting since midnight [11].
Diabetes mellitus was defined as fasting blood glucose
7.0mmol/l, using any hypoglycaemic medication, and/or
a 2 h plasma glucose 11.1 in an oral glucose tolerance test
(performed if fasting glucose 5.6mmol/l).
Statistical analysis
To examine the associations between renal markers and
carotid atherosclerosis, we created tertiles of the study
population according to serum cystatin C, serum creatinine
and GFR levels. The upper tertile was subdivided into
three groups, as levels of renal markers were relatively low in
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this middle-aged population, compared to older adults [6],
and to be able to assess the effect of elevated renal markers,
similar to a previous study [6]. We used linear regression
models to assess the association between those markers and
carotid IMT. To compare the overall prediction of tradi-
tional and new risk factors on IMT, we used adjusted R2. For
each outcome, the multivariate models included the same
covariates based on clinical plausibility (e.g. diabetes, lipids).
We hypothesized several interactions: the relationships
between renal markers and carotid atherosclerosis might
differ by age, gender, hypertension and diabetes status.
Results were reported as odds ratio (OR) with 95%
confidence intervals (CI) or mean adjusted values for IMT.




The mean age of the study sample was 52 years, and
55% were women. A majority of this population
sample of Seychelles was of African descent (90%)
with small minorities of European, Indian and Chinese
descent. Serum cystatin C was higher in older than
younger participants and in men than women
(Table 1). Higher levels of cystatin C were associated
with smoking and most traditional cardiovascular risk
factors. Participants with higher serum cystatin had
higher serum creatinine and lower GFR (P for
trend< 0.001), but the prevalence of microalbuminuria
did not significantly differ among tertiles of cystatin C
(P for trend¼ 0.10). Cystatin C was correlated with
creatinine (r¼ 0.60, P< 0.001) and inversely correlated
with GFR (r¼0.41, P< 0.001). Participants with
microalbuminuria were older and more likely to have
glucose abnormalities, high blood pressure, BMI and
triglycerides (Table 2). Cystatin C, but not GFR, was
significantly higher in those with microalbuminuria
(P¼ 0.003). Adjustment for age diminished the differ-
ence in cystatin C according to microalbuminuria
(P¼ 0.02), and removed the association between
cystatin C and systolic blood pressure (P¼ 0.36). All
other relationships did not meaningfully change after
adjusting for age. A total of 24 participants (5%) had a
GFR <60ml/min/1.73m2.
Traditional risk factors, serum cystatin C,
microalbuminuria and carotid IMT
Carotid IMT was strongly associated with age, but not
with gender (Table 3). In analyses adjusted for age
and gender, IMT was also strongly associated with
most traditional risk factors and microalbuminuria








Number of participants 178 163 182
Age (years) 50.1 7.7 52.4 6.7 54.6 6.8 <0.001
Woman (%) 61 54 50 0.03
Current smoker (%) 10 18 19 0.01
Glucose metabolism 0.08
Normal fasting glucose (%) 45 43 39
Impaired FG/GT (%) 29 37 42
Diabetes mellitus (%) 26 19 19
BP stages [mmHg (%)c] 0.04
Normal BP <140/90 59 53 47
Stage 1 BP 140–159/90–99 29 25 32
Stage 2 BP 160/100 12 22 20
Body mass index (kg/m)2 27.7 5.6 27.7 5.5 29.2 5.5 0.02
Systolic BP (mmHg) 132.1 17.6 135.3 18.8 137.8 23.1 0.007
Diastolic BP (mmHg) 85.6 11.1 87.4 11.6 87.8 13.5 0.08
LDL-cholesterol (mmol/l) 3.5 1.2 3.9 1.2 4.1 1.3 <0.001
HDL-cholesterol (mmol/l) 1.3 0.5 1.4 0.5 1.3 0.5 0.43
Triglycerides (mmol/l) 1.1 1.0 1.2 1.2 1.3 0.8 0.04
Glucose (mmol/l) 6.9 2.9 6.4 1.9 6.5 2.3 0.13
Serum creatinine (mmol/l) 73.6 14.0 79.2 14.6 92.0 29.1 <0.001
Estimated GFRd (ml/min/1.73m2) 98.6 19.1 91.4 19.6 79.9 19.9 <0.001
Serum cystatin C (mg/l) 0.68 0.09 0.83 0.03 1.03 0.22 <0.001
Microalbuminuriae (%) 19 16 26 0.10
BP, blood pressure; impaired FG/GT, impaired fasting glucose defined as fasting glucose 5.6–6.9mmol/l [40] or impaired glucose tolerance
defined as 2 h plasma glucose 7.8–11.0mmol/l in an oral glucose tolerance test [41].
aValues are mean SD or percentages.
bChi square tests for trend for categorical variables and F-tests for trend for continuous variables across tertiles of cystatin C.
cBlood pressure stages according to the JNC-7 report [42]. Participants using anti-hypertensive medications with a measured blood pressure
<140/90 were included in the blood pressure stage 1.
dGFR estimated using the abbreviated modification of diet in renal disease (MDRD) equation [18].
eMicroalbuminuria defined as urinary albumin excretion of 30–300mg albumin/g creatinine [17].
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Table 3. Multivariate analysis of traditional cardiovascular risk factors, serum cystatin C and microalbuminuria on carotid intima-media
thickness (IMT)








0.107b 0.152 0.155 0.157
b(SE) P b(SE) P b(SE) P b(SE) P
Age (years) 8.1 (1.0) <0.001 7.2 (1.1) <0.001 7.6 (1.1) <0.001 7.1 (1.1) <0.001
Gender 13.2 (14.8) 0.37 8.0 (16.2) 0.62 5.9 (16.2) 0.72 7.3 (16.2) 0.65
Glucose metabolism 0.001 0.02 0.02 0.04
Impaired FG/GT 23.3 (16.8) 12.3 (17.0) 13.6 (17.1) 12.1 (17.0)
Diabetes mellitus 66.6 (20.2) 49.9 (20.8) 48.1 (21.1) 43.9 (21.0)
BP stages 0.06 0.09 0.06 0.23
Stage 1 11.6 (17.5) 6.7 (17.2) 5.1 (17.2) 3.4 (17.3)
Stage 2 38.0 (20.5) 34.2 (20.3) 37.7 (20.3) 24.9 (20.8)
LDL-cholesterol (mmol/l) 22.7 (5.9) <0.001 19.0 (6.1) 0.002 20.5 (6.2) 0.001 19.0 (6.1) 0.002
HDL-cholesterol (mmol/l) 59.4 (15.0) <0.001 49.9 (16.7) 0.003 48.0 (16.8) 0.004 49.4 (16.7) 0.003
Triglycerides (mmol/l) 8.3 (7.2) 0.25 12.6 (8.1) 0.12 12.1 (8.0) 0.13 13.6 (8.0) 0.09
Current smoking 7.0 (21.8) 0.75 6.5 (21.7) 0.76 11.6 (21.8) 0.60 6.6 (21.7) 0.76
Serum cystatin C (mg/l) 0.76 0.37
Tertile 1 (<0.78) 0 0
Tertile 2 (0.78–0.88) 33.9 (18.5) 37.9 (18.4)
Tertile 3a (0.89–0.93) 14.6 (25.5) 24.3 (25.3)
Tertile 3b (0.94–1.02) 7.3 (25.2) 2.7 (25.4)
Tertile 3c (1.02) 29.6 (26.0) 43.5 (25.8)
Urinary albumin excretion
(mg albumin/g creatinine)
Normal (<30mg/g) 0 0
Microalbuminuria
(30–300mg/g)
52.9 (18.3) 0.004 37.5 (18.8) 0.047
aAdjusted for age, gender, smoking status, diabetes mellitus, blood pressure stages, LDL-cholesterol, HDL-cholesterol and triglycerides.
bAdjusted R2 for the model that examined the prediction of age and gender on IMT.
Table 2. Baseline characteristics of study population according to microalbuminuriaa
Characteristics Urinary albumin excretion (mg albumin/g creatinine)
Normal (<30mg/g) Microalbuminuria (30–300mg/g) Pb
No. of participants 417 106
Age (years) 51.9 7.4 54.1 6.7 0.006
Woman (%) 55 55 0.94
Current smoker (%) 16 15 0.85
Glucose metabolism <0.001
Normal fasting glucose (%) 46 31
Impaired FG/GT (%) 37 31
Diabetes mellitus (%) 17 38
BP stages (mmHg %) <0.001
Normal, BP <140/90 58 31
Stage 1, BP 140–159/90–99 28 34
Stage 2, BP 160/100 14 35
Body mass index (kg/m2) 27.9 5.9 29.5 5.4 0.01
Systolic BP (mmHg) 132.1 17.9 146.9 23.7 <0.001
Diastolic BP (mmHg) 85.3 11.3 93.3 13.4 <0.001
LDL-cholesterol (mmol/l) 3.8 1.2 4.0 1.5 0.21
HDL-cholesterol (mmol/l) 1.4 0.5 1.3 0.5 0.08
Triglycerides (mmol/l) 1.1 0.9 1.5 1.3 0.001
Glucose (mmol/l) 6.3 2.1 7.7 3.2 <0.001
Serum creatinine (mmol/l) 80.8 18.0 85.3 33.5 0.06
Estimated GFR (ml/min/1.73m2) 90.2 19.9 88.6 24.9 0.48
Serum cystatin C (mg/l) 0.83 0.16 0.90 0.31 0.003
BP, blood pressure; impaired FG/GT, impaired fasting glucose or impaired glucose tolerance.
aValues are meanSD or percentages.
bChi square tests for categorical variables and t-tests for continuous variables.
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(P¼ 0.004), but not with cystatin C (P for trend¼
0.76). In multivariate analyses adjusted for age, gender
and traditional risk factors, the association between
microalbuminuria and IMT remained (P¼ 0.047),
while there was no association between cystatin C
and IMT (P for trend¼ 0.37). The relationships
between all traditional risk factors, microalbuminuria,
cystatin C and IMT did not differ by gender (each
interaction P-value >0.05). The overall prediction of
traditional risk factors on IMT did not differ from
models that included traditional risk factors, cystatin C
and microalbuminuria (adjusted R2 0.152 vs 0.157).
Measures of renal function and carotid IMT
Carotid IMT significantly increased with decreasing
GFR (from 728 to 809 mm, P for trend¼ 0.002), but not
with serum cystatin C and creatinine (Table 4).
Microalbuminuria was associated with higher IMT
(802 vs 732 mm, P< 0.001). In multivariate analysis
adjusted for age, gender and traditional risk factors, the
association between GFR and IMT disappeared (P for
trend¼ 0.33). The associations between cystatin C,
creatinine and IMT were further reduced (P for
trend¼ 0.37 and 0.24, respectively). The association
between microalbuminuria and IMT was reduced
(regression coefficient reduced by about a third), but
remained borderline significant (P¼ 0.047). The rela-
tionships between microalbuminuria and carotid IMT
did not differ by age, gender, presence of hypertension
or diabetes (each interaction P value >0.20). Using
creatinine, GFR and cystatin C as continuous variables
yielded similar results, with no statistically significant
associations with IMT. In multivariate analyses, each
SD increase of 22 mmol/l in creatinine was associated
with an increase in IMT of 5 mm (P¼ 0.53), each SD
decrease of GFR with an increase in IMT of 3 mm
(P¼ 0.71) and each SD increase of 0.20mg/l of cystatin
C with a decrease in IMT of 5 mm (P¼ 0.50). In
comparison, as shown in Table 4, presence vs absence
of microalbuminuria was associated with an increase in
IMT of 37 mm (P¼ 0.047).
Discussion
In this population-based study of middle-aged adults,
microalbuminuria, but not cystatin C, was associated
with carotid atherosclerosis independently of age and
traditional cardiovascular risk factors. In contrast, the
relationship between cystatin C and carotid athero-
sclerosis appeared to be largely confounded by age and
other cardiovascular risk factors. We found no
consistent evidence that serum cystatin C had a
stronger relationship with carotid atherosclerosis in
middle-aged adults than serum creatinine or GFR in
this population that mostly included participants with
mild or no renal dysfunction.
Previous prospective studies in the elderly have
found that serum cystatin C was a stronger predictor
of cardiovascular events and cardiovascular mortality
than either serum creatinine or GFR [6,9], including
in those with a GFR 60ml/min/1.73m2 [24].
Our results on cystatin C and IMT could only be
directly compared with one small cross-sectional study
of 60 hypertensive Japanese patients (mean age: 58
years) that found a correlation between serum cystatin
C levels and IMT (r¼ 0.54, P< 0.001) [25], but did not
adjust for potential confounders and only presented
Pearson correlation coefficients that have been shown
to be very sensitive to outliers, yielding to potentially
biased results [26]. Moreover, a prospective study in
middle-aged adults did not confirm the strong associa-
tion found in older adults [27]. In this study, the
association between cystatin C and coronary event was
borderline significant after adjustment for age and
traditional risk factors (RR per SD: 1.19, 95%CI:
1.01–1.40) and no longer statistically significant after
further adjustment for C-reactive protein (CRP) (RR:
1.13, 95%CI: 0.95–1.34). Several potential explana-
tions could explain why the association between serum
cystatin C and CVD might differ between middle-aged
adults in our cross-sectional data and in the prospec-
tive study described above [27] and older adults in
prospective studies [6,9]. First, most participants in our
study population had relatively low levels of cystatin
C, as compared with studies that included older adults
[6] or large proportions of patients with renal
dysfunction [28,29]. Those in the first two tertiles of
cystatin had lower cystatin than participants aged 65
in the second quintile of cystatin in the Cardiovascular
Health Study, and the risk of myocardial infarction did
not significantly differ between the 1st and 2nd
quintiles (adjusted hazard ratio: 0.97, 95%CI: 067–
1.41) in this previous study [6]. Only 10 (2%) of our
participants would belong to the 5th quintile of
cystatin of this study. Similarly, serum creatinine
levels in our sample were lower and GFR higher
than in older adults, and only 24 participants (5%) had
chronic kidney disease of at least stage 3
(GFR< 60ml/min/1.73m2) [30]. Thus, our popula-
tion-based results are, expectedly, not representative of
adults with advanced renal disease or patients with a
GFR< 60ml/min/1.73m2 [30] who have an increased
risk of CVD [7]. The fact that most participants of our
study had a GFR 60ml/min/1.73m2 (95%) might
explain why markers of glomerular filtration (serum
creatinine and cystatin C) were not associated with
carotid IMT. However, even those in the highest
subtertile of tertile 3 of cystatin in our study popula-
tion did not have an increased risk of carotid
atherosclerosis in multivariate analyses. The levels of
cystatin C in our population in the African region were
also similar to levels found in an European prospective
study that included men aged 50–59 years of the
general population [27]. Secondly, in our population,
cystatin C was strongly associated with some tradi-
tional risk factors, such as low density lipoprotein
(LDL)-cholesterol and smoking status, that were not
associated with cystatin C in an older population [6].
Moreover, a previous study has found that cystatin C
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was influenced by several factors other than renal
function alone, such as BMI and smoking [31]. It
should be noted that cystatin C was not independently
associated with IMT in our study, although the
participants, despite being truly representative of the
general population, were at relatively high cardiovas-
cular risk with a high prevalence of cardiovascular risk
factors. Another explanation for these age differences
might be differences in study designs (cross-sectional vs
prospective data).
Despite some conflicting results [32], several cross-
sectional studies found that microalbuminuria was
associated with higher IMT [14,33,34], similar to our
data. However, previous studies were limited by the
focus on high-risk adults in selected settings, such as
hypertensive [33] or diabetic subjects [34], or by the
lack of adjustment for diabetes [14]. One study in the
MESA (the Multi-Ethnic Study of Atherosclerosis)
cohort found an association between microalbumi-
nuria and carotid IMT in unadjusted analyses
(mean SE: 900 10 mm in those with microalbumi-
nuria vs 850 3 mm in those without, P< 0.001), but
this association was no longer significant in multi-
variate analyses [32]. However, microalbuminuria was
positively associated with other markers of subclinical
cardiovascular disease, such as coronary artery calci-
fication and left ventricular mass. One potential
explanation for the differences between our results
and the results in the MESA cohort might be the older
age of the population in MESA (mean age 63 years,
range 45–85 years). Another study found an associa-
tion between microalbuminuria and carotid IMT in
unadjusted analyses, which remained significant in
multivariate analyses in diabetics, but not in non-
diabetic participants [35], while the relationship
between microalbuminuria and carotid IMT did not
differ by presence of diabetes in our study population.
Potential explanations for the differences with our data
might be the unusual way to measure IMT (only left
carotid artery measured) and the likely inclusion of
mostly White subjects, while our study includes
predominantly persons of African descent.
The mechanisms by which microalbuminuria
increases cardiovascular risk are still uncertain.
Traditional risk factors [36], inflammatory markers
[36] and endothelial dysfunction [37] may contribute to
increased cardiovascular risk in subjects with
microalbuminuria.
Our study has several limitations. As the study was
cross-sectional, we cannot determine the direction of
the association between renal markers and carotid
atherosclerosis. For example, it has been suggested that
microalbuminuria might just be a marker of general-
ized vascular dysfunction [38], and the substantial
attenuation of the magnitude of the association
between microalbuminuria and carotid IMT in our
study when adjusting for risk factors, such as
hypertension and diabetes, may be consistent with
such a mechanism. Although microalbuminuria was
independently associated with carotid IMT, the mag-
nitude of the associated risks for future CVD would
likely be low. In the Cardiovascular Health Study, a
difference of 200mm in IMT was associated with a
27% increased risk of myocardial infarction [39].
In our study, the IMT difference associated with
microalbuminuria was 70 mm, which would
Table 4. Carotid intima-media thickness (IMT) in mm according to measures of renal function
Unadjusted Age-adjusted Multivariate-adjusteda
Mean (95% CI), mm Pb Mean (95% CI), mm Pb Mean (95% CI), mm Pb
Urinary albumin excretion (mg albumin/g creatinine)
Normal (<30mg/g) 732 (715–749) <0.001 679 (657–700) 0.004 678 (656–699) 0.047
Microalbuminuria (30–300mg/g) 802 (768–836) 731 (695–768) 715 (678–753)
Serum cystatin C (mg/l) 0.10c 0.70c 0.37c
Tertile 1 (<0.78) 743 (716–769) 702 (675–728) 702 (675–728)
Tertile 2 (0.78–0.88) 728 (700–755) 667 (637–697) 664 (634–693)
Tertile 3a (0.89–0.93) 754 (709–800) 686 (640–732) 678 (632–723)
Tertile 3b (0.94–1.02) 783 (739–828) 679 (658–700) 699 (653–745)
Tertile 3c (1.02) 763 (718-808) 670 (622–718) 658 (611–706)
Serum creatinine, mmol/l 0.16c 0.29c 0.24c
Tertile 1 (<72) 740 (714–767) 687 (659–715) 680 (651–710)
Tertile 2 (73–85) 738 (711–765) 673 (644–703) 672 (643–701)
Tertile 3a (86–92) 732 (684–780) 674 (626–721) 668 (621–716)
Tertile 3b (93–101) 791 (747–835) 740 (697–784) 741 (697–785)
Tertile 3c (102) 756 (710–801) 683 (637–729) 683 (635–732)
Estimated GFR, ml/min/1.73m2 0.002c 0.13c 0.33c
Tertile 1 (97) 728 (702–754) 680 (652–708) 683 (656–711)
Tertile 2 (79–96) 736 (710–762) 690 (663–718) 684 (656–712)
Tertile 3a (73–78) 758 (715–802) 690 (645–736) 681 (635–726)
Tertile 3b (67–72) 766 (718–814) 692 (643–742) 687 (638–737)
Tertile 3c (<67) 809 (761–857) 725 (675–776) 711 (661–761)
aAdjusted for age, gender, smoking status, diabetes mellitus, blood pressure stages, LDL-cholesterol, HDL-cholesterol and triglycerides.
bChi-square tests for trend for multilevel categorical variables and statistical test from the linear regression model for other variables.
cChi-square tests for trend.
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correspond to a 9% increase in cardiovascular risk. As
our measurement of microalbuminuria was
semi-quantitative and dichotomized, we could not
examine whether higher levels of microalbuminuria
would be linearly associated with higher IMT. We also
had limited power to perform subgroup analyses,
because of the relatively small sample size. Strengths
of our study sample were its population-based design
with a high participation rate, which allows inferring
findings to the general population of middle-aged
adults, and the availability of all traditional cardio-
vascular risk factors, which allowed adjusting for
several potential confounding variables in our analysis.
Also, few studies had previously assessed the relation-
ship between cystatin C and microalbuminuria and
carotid IMT in persons of African descent, less so in
populations in the African continent.
In summary, microalbuminuria is associated with
carotid atherosclerosis, as assessed by IMT, beyond
traditional cardiovascular risk factors among middle-
aged adults, but not cystatin C. The absence of an
association in this population-based cross-sectional
study of middle-aged adults and an association found
in prospective studies among older adults suggests that
the relationship between markers of renal function and
cardiovascular disease might differ between middle-
aged and older adults and/or depending of the target
population. Before using cystatin C for cardiovascular
risk stratification in clinical practice, the relationships
between cystatin C, microalbuminuria and CVD
should be further examined in prospective studies
that include middle-aged adults.
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